Please login to the form below
JAK inhibitors
This page shows the latest JAK inhibitors news and features for those working in and with pharma, biotech and healthcare.
EMA issues new guidance to limit use of JAK inhibitors for chronic inflammatory disorders
The EMA outlined that the product information for JAK inhibitors for these indications will be updated with new recommendations and warnings. ... The JAK inhibitors Jakavi and Inrebic, which are used to treat myeloproliferative disorders, were not
Latest news
-
GSK’s application for momelotinib in myelofibrosis with anaemia accepted by FDA
with myelofibrosis who were symptomatic and anaemic and had been previously treated with an FDA-approved Janus kinase (JAK) inhibitor. ... eventually. Furthermore, currently approved JAK inhibitors only address symptoms and splenomegaly and are
-
Eli Lilly and Incyte's Olumiant receives FDA approval for alopecia
The treatment is not recommended for use in combination with other Janus kinase (JAK) inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
-
Researchers use AI to identify drugs that could be repurposed for Alzheimer’s
Eli Lilly's JAK inhibitor Olumiant identified as a potential treatment for repurposing. ... JAK inhibitors are commonly used to treat conditions such as rheumatoid arthritis and blood cancers, and block the action of JAK proteins, which play a role in
-
Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19
A study of Eli Lilly’s JAK inhibitor Olumiant in combination with Gilead’s antiviral med remdesivir met its primary endpoint in patients hospitalised with COVID-19. ... therapies. Researchers have theorised that anti-inflammatory drugs, such as IL-6
-
New study identifies drugs that are safe to use in COVID-19 treatment
The study also found that other types of drugs – such as TNF blockers and JAK inhibitors – are also safe to use in the treatment of COVID-19.
More from news
Approximately 2 fully matching, plus 26 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
JAK inhibitors such as Xeljanz and Rinvoq. ... It faces competition from entrenched generic metformin and sulphonylureas, as well as from more novel drug classes, particularly SGLT-2, inhibitors, DDP4 inhibitors and injectable GLP-1 agonists.
-
20 for 2020 – Five pharma leaders to watch in 2020
pneumococcal vaccine due to be filed next year that would extend its $3.4bn Prevnar franchise, a Clostridium difficile vaccine in phase 3 and JAK inhibitors for atopic dermatitis and alopecia. ... and filgotinib’s anticipated launch this year meets
-
Pharma deals during December 2012
In return for this hefty premium, Gilead acquires a company with an annual cash burn of $30m developing orally active JAK 1 / JAK 2 kinase inhibitors and with a lead product, ... Company acquisition. JAK kinase inhibitors development company. 510. Sutro /
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Today, some of the most innovative therapies in development are Janus kinase (JAK) inhibitors, and the latest ‘game changer’ Tyrosine kinase 2 (TYK2) inhibitors. ... The healthcare press has described TYK2 inhibitors as having the potential
-
Webcast: Navigating new frontiers: Ways to find space in the future RA market
Analysis of Therapy Watch data, a real-time syndicated market tracking tool and Living With data, our syndicated patient report series shows that JAK inhibitors have already made a strong impression ... Topics covered in the webcast include:. The
-
Live webinar: Navigating new frontiers: Ways to find space in the future RA market
Topics to be covered include:. The European RA market. Current status and market situation of JAK inhibitors (key EU5 countries). ... Profile of physicians prescribing JAKS. Country differences. The future of new classes of JAK inhibitors.
-
The Biosimilar Challenge
Source: Adelphi Online Survey with N=55 Trust Pharmacists/CCG Commissioners/CCG HMM/HMOs. Theoretically cost-savings should be freeing up funds for new branded therapies such as JAK Inhibitors but
-
Brand leaders in RA will lose market share, predict rheumatologists
JAK-inhibitors were the most commonly mentioned class, with Xeljanz the most frequently cited product.
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
Onyx Health
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
